AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Wrapmanager Inc.

Wrapmanager Inc. reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 9.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,693 shares of the company’s stock after selling 473 shares during the period. Wrapmanager Inc.’s holdings in AstraZeneca were worth $366,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. McClarren Financial Advisors Inc. grew its stake in shares of AstraZeneca by 320.8% in the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock valued at $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. acquired a new position in AstraZeneca in the 2nd quarter valued at about $26,000. Capital Performance Advisors LLP purchased a new stake in AstraZeneca during the third quarter worth about $28,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the first quarter worth about $29,000. Finally, Hobbs Group Advisors LLC acquired a new position in AstraZeneca during the 2nd quarter worth $35,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen increased their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Up 0.6 %

Shares of NASDAQ:AZN opened at $63.80 on Wednesday. The company has a market cap of $197.82 billion, a price-to-earnings ratio of 30.53, a PEG ratio of 1.17 and a beta of 0.47. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The firm’s 50-day simple moving average is $74.34 and its 200-day simple moving average is $78.06. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the firm earned $0.87 EPS. As a group, equities research analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.